Literature DB >> 27966541

Prevalence, birth incidence, and penetrance of von Hippel-Lindau disease (vHL) in Denmark.

Marie Louise Mølgaard Binderup1, Michael Galanakis1, Esben Budtz-Jørgensen1,2, Michael Kosteljanetz3, Marie Luise Bisgaard1.   

Abstract

Von Hippel-Lindau disease (vHL) is a rare hereditary tumour predisposition with multiorgan involvement that is not always easily recognized. The disease is reported to be almost fully penetrant at age 60 years. Previous estimates of vHL prevalence and incidence are all regional and vary widely. Most are >20 years old and prone to selection bias because of inclusion of only clinically affected vHL patients who were diagnosed before genetic testing was available. In an unselected cohort of all known Danish carriers of a disease-causing VHL variant, we assessed vHL penetrance on a national basis. We further used national health registers to identify individuals who fulfilled the clinical diagnostic vHL criteria based on their registered diagnostic codes, but had not been diagnosed with vHL. We also assessed the medical histories of first-degree relatives to identify familial cases. This study gives the first national estimates of vHL prevalence (1 in 46 900 individuals) and birth incidence (1 in 27 300 live births). vHL has been underdiagnosed in Denmark, and as many as 25% of the overall vHL cohort (diagnosed+undiagnosed patients) have a missed diagnosis in spite of fulfilling the international diagnostic criteria. We found an overall penetrance of 87% at age 60 years. When considering only vHL patients who have not attended surveillance, 20% will still be asymptomatic at age 60 years. This should be considered in the context of genetic counselling, especially when assessing the risk of vHL in asymptomatic adult first-degree relatives who are often not genetically tested.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27966541      PMCID: PMC5315510          DOI: 10.1038/ejhg.2016.173

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  21 in total

Review 1.  Genetics of familial renal cancers.

Authors:  Eamonn R Maher
Journal:  Nephron Exp Nephrol       Date:  2010-11-11

2.  Surveillance in von Hippel-Lindau disease (vHL).

Authors:  M L M Poulsen; E Budtz-Jørgensen; M L Bisgaard
Journal:  Clin Genet       Date:  2009-10-15       Impact factor: 4.438

3.  A genetic register for von Hippel-Lindau disease.

Authors:  I R Maddock; A Moran; E R Maher; M D Teare; A Norman; S J Payne; R Whitehouse; C Dodd; M Lavin; N Hartley; M Super; D G Evans
Journal:  J Med Genet       Date:  1996-02       Impact factor: 6.318

Review 4.  Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus.

Authors:  H P Neumann; O D Wiestler
Journal:  Lancet       Date:  1991-05-04       Impact factor: 79.321

5.  Von Hippel-Lindau disease germline mutations in Mexican patients with cerebellar hemangioblastoma.

Authors:  Astrid Rasmussen; Sonia Nava-Salazar; Petra Yescas; Elisa Alonso; Rogelio Revuelta; Iván Ortiz; Samuel Canizales-Quinteros; María Teresa Tusié-Luna; Marisol López-López
Journal:  J Neurosurg       Date:  2006-03       Impact factor: 5.115

6.  The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system.

Authors:  S Gläsker; B U Bender; T W Apel; E Natt; V van Velthoven; R Scheremet; J Zentner; H P Neumann
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

7.  Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service.

Authors:  D G Evans; E Howard; C Giblin; T Clancy; H Spencer; S M Huson; F Lalloo
Journal:  Am J Med Genet A       Date:  2010-02       Impact factor: 2.802

8.  Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene.

Authors:  F M Richards; S J Payne; B Zbar; N A Affara; M A Ferguson-Smith; E R Maher
Journal:  Hum Mol Genet       Date:  1995-11       Impact factor: 6.150

9.  Frequency of Von Hippel-Lindau germline mutations in classic and non-classic Von Hippel-Lindau disease identified by DNA sequencing, Southern blot analysis and multiplex ligation-dependent probe amplification.

Authors:  F J Hes; R B van der Luijt; A L W Janssen; R A Zewald; G J de Jong; J W Lenders; T P Links; G P M Luyten; R H Sijmons; H J Eussen; D J J Halley; C J M Lips; P L Pearson; A M W van den Ouweland; D F Majoor-Krakauer
Journal:  Clin Genet       Date:  2007-08       Impact factor: 4.438

10.  Von Hippel-Lindau disease: a genetic study.

Authors:  E R Maher; L Iselius; J R Yates; M Littler; C Benjamin; R Harris; J Sampson; A Williams; M A Ferguson-Smith; N Morton
Journal:  J Med Genet       Date:  1991-07       Impact factor: 6.318

View more
  9 in total

1.  Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.

Authors:  Eric Jonasch; Frede Donskov; Othon Iliopoulos; W Kimryn Rathmell; Vivek K Narayan; Benjamin L Maughan; Stephane Oudard; Tobias Else; Jodi K Maranchie; Sarah J Welsh; Sanjay Thamake; Eric K Park; Rodolfo F Perini; W Marston Linehan; Ramaprasad Srinivasan
Journal:  N Engl J Med       Date:  2021-11-25       Impact factor: 176.079

2.  Germline mutations in the new E1' cryptic exon of the VHL gene in patients with tumours of von Hippel-Lindau disease spectrum or with paraganglioma.

Authors:  Bruna Calsina; Shahida Flores; Sophie Giraud; Marion Lenglet; Alexandre Buffet; Pauline Romanet; Elisa Deflorenne; Javier Aller; Isabelle Bourdeau; Brigitte Bressac-de Paillerets; María Calatayud; Caroline Dehais; Erwan De Mones Del Pujol; Atanaska Elenkova; Philippe Herman; Peter Kamenický; Sophie Lejeune; Jean Louis Sadoul; Anne Barlier; Stephane Richard; Judith Favier; Nelly Burnichon; Betty Gardie; Patricia L Dahia; Mercedes Robledo; Anne-Paule Gimenez-Roqueplo
Journal:  J Med Genet       Date:  2020-01-29       Impact factor: 6.318

3.  The incidence of consecutive manifestations in Von Hippel-Lindau disease.

Authors:  Anouk N A van der Horst-Schrivers; Wim J Sluiter; Roeliene C Kruizinga; Rachel S van Leeuwaarde; Rachel Giles; Maran J W Olderode-Berends; Thera P Links
Journal:  Fam Cancer       Date:  2019-07       Impact factor: 2.375

4.  Whole-exome sequencing and immunohistochemistry findings in von Hippel-Lindau disease.

Authors:  Xiaopeng Guo; Lu Gao; Xiafei Hong; Dan Guo; Wenyu Di; Xiaoman Wang; Zhiqin Xu; Bing Xing
Journal:  Mol Genet Genomic Med       Date:  2019-07-17       Impact factor: 2.183

5.  Genetic Counseling and Long-Term Surveillance Using a Multidisciplinary Approach in von Hippel-Lindau Disease.

Authors:  Sun Joo Yoon; Won Kyung Kwon; Geehay Hong; Ja-Hyun Jang; Byong Chang Jeong; Jae Hyeon Kim; Jong-Won Kim
Journal:  Ann Lab Med       Date:  2022-05-01       Impact factor: 3.464

Review 6.  Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: not a needle in a haystack.

Authors:  João Castro-Teles; Bernardo Sousa-Pinto; Sandra Rebelo; Duarte Pignatelli
Journal:  Endocr Connect       Date:  2021-10-27       Impact factor: 3.335

7.  VHL mosaicism: the added value of multi-tissue analysis.

Authors:  Leslie E Oldfield; Jessica Grzybowski; Sylvie Grenier; Elizabeth Chao; Gregory S Downs; Kirsten M Farncombe; Tracy L Stockley; Ozgur Mete; Raymond H Kim
Journal:  NPJ Genom Med       Date:  2022-03-18       Impact factor: 8.617

8.  An optimized protocol for evaluating pathogenicity of VHL germline variants in patients suspected with von Hippel-Lindau syndrome: Using somatic genome to inform the role of germline variants.

Authors:  Diane R Koeller; Danielle K Manning; Alison Schwartz; Anu Chittenden; Connor P Hayes; Feruza Abraamyan; Huma Q Rana; Neal I Lindeman; Judy E Garber; Arezou A Ghazani
Journal:  MethodsX       Date:  2022-06-18

Review 9.  Is There a Role for Biomarkers in Surveillance of Pancreatic Neuroendocrine Neoplasms in Von Hippel-Lindau Disease?

Authors:  Myrthe R Naber; Saya Ahmad; Annemarie A Verrijn Stuart; Rachel H Giles; Gerlof D Valk; Rachel S van Leeuwaarde
Journal:  J Endocr Soc       Date:  2021-12-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.